公开(公告)号：US20160129045A1

公开(公告)日：2016-05-12

申请号：US14925991

申请日：2015-10-29

Applicant: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Won Bae JEON ,  Seong Kyoon CHOI ,  Jin Kyu PARK

IPC: A61K35/35 ,  A61K38/39 ,  A61K47/48 ,  A61K9/00

CPC classification number: A61K38/39 ,  A61K35/28 ,  A61K35/30 ,  A61L26/0047 ,  A61L26/0057 ,  A61K2300/00

Abstract: Provided is a composition for wound-healing containing adult stem cells and elastin-like polypeptides, and more specifically, to a composition for wound-healing capable of effectively treating skin wounds by simultaneously administering elastin-like polypeptides along with adult stem cells thereby increasing the viability of the adult stem cells transplanted on the wounds and promoting angiogenesis.

Abstract translation: 提供了一种用于伤口愈合的组合物，其包含成体干细胞和弹性蛋白样多肽，更具体地，涉及一种用于伤口愈合的组合物，其能够通过同时施用弹性蛋白样多肽以及成体干细胞来有效治疗皮肤伤口，由此增加 成体干细胞移植在伤口上并促进血管发生的活力。

公开(公告)号：US20230174931A1

公开(公告)日：2023-06-08

申请号：US17437411

申请日：2020-03-11

Applicant: Daegu Gyeongbuk Institute of Science and Technology

Inventor： Cheil MOON ,  Won Bae JEON ,  Sam Hwan KIM ,  Seong Kyoon CHOI

IPC: C12N5/0793

CPC classification number: C12N5/062 ,  C12N2533/50

Abstract: The present invention relates to a method for culturing neural stem cells into spheroids, the method including: culturing neural stem cells in a culture vessel coated with a protein containing a VGVPG pentapeptide and an RGD integrin receptor ligand; and isolating the neural stem cells that are aggregated and formed into spheroids during the culturing.

公开(公告)号：US20150030655A1

公开(公告)日：2015-01-29

申请号：US14273557

申请日：2014-05-09

Applicant: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Won Bae JEON ,  Seong Kyoon CHOI

IPC: A61L27/18 ,  A61L27/34 ,  A61L27/54

CPC classification number: A61L27/18 ,  A61L27/34 ,  A61L27/54 ,  A61L27/56 ,  A61L2300/21 ,  A61L2300/428 ,  C08L89/00 ,  C08L67/04

Abstract: Disclosed is a PLGA (poly(D,L-lactide-co-glycolide)) cell scaffold. The cell scaffold is based on a PLGA scaffold, which is an FDA-approved material with no cytotoxicity, and overcomes the problem with conventional PLGA scaffolds of poor cell adhesion.

Abstract translation: 公开了一种PLGA（聚（D，L-丙交酯 - 共 - 乙交酯））细胞支架。 细胞支架基于PLGA支架，其是经FDA认可的材料，没有细胞毒性，并且克服了传统的PLGA支架不良细胞粘附的问题。

公开(公告)号：US20230406886A1

公开(公告)日：2023-12-21

申请号：US18037549

申请日：2021-05-06

Applicant: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Iksoo CHANG ,  Mooseok KANG ,  Ae Ree LEE ,  Souk SEO ,  Woo Kyung YU ,  Wookbong KWON ,  Hee Yeon KIM ,  Song PARK ,  Seong Kyoon CHOI ,  Min Gi KIM ,  Sang Yeol KIM ,  Hyo Eun KIM ,  Ga Hee MIN ,  Seongjun PARK ,  Kyung Eun LEE ,  Juhwan LEE ,  Sang Ho JI ,  Min Jee CHOI ,  Jae Seok CHOI ,  Young-Ho LEE

IPC: C07K14/00 ,  A61P31/14 ,  G01N33/569

CPC classification number: C07K14/001 ,  A61P31/14 ,  G01N33/56983 ,  A61K38/00

Abstract: The present invention relates to coronavirus infectious disease COVID-19 therapeutic proteins CTP alpha, CTP beta, CTP gamma, CTP delta, and uses thereof. Compared to a known peptide (P6) which mimics the binding site of a receptor binding domain (RBD) of SARS-CoV and angiotensin-converting enzyme 2 (ACE2), the therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention comprise a novel part obtained by adding a novel sequence of amino acids, wherein the interaction of atoms constituting the amino acids has been fundamentally designed in order to strengthen the binding of SARS-CoV2 to a novel epitope of RBD. The present invention provides therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta having a novel design and capable of binding more strongly than known peptides due to being creative designs of the extended therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta, wherein the therapeutic proteins can additionally interact with charged amino acids of D420 and K458 on the rear side of the conventional binding interface between RBD and hACE2 or additionally interact with charged amino acids such as R454, K458, D467, and E471. The therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention have the potential of being highly applicable as COVID-19 therapeutic agents.

公开(公告)号：US20230303627A1

公开(公告)日：2023-09-28

申请号：US18018364

申请日：2021-05-11

Applicant: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Iksoo CHANG ,  Mooseok KANG ,  Ae Ree LEE ,  Souk SEO ,  Wookbong KWON ,  Hee Yeon KIM ,  Song PARK ,  Woo Kyung YU ,  Young-Ho LEE ,  Sang Ho JI ,  Seong Kyoon CHOI ,  Min Gi KIM ,  Sang Yeol KIM ,  Hyo Eun KIM ,  Ga Hee MIN ,  Seongjun PARK ,  Myeong Won OH ,  Kyung Eun LE ,  Juhwan LEE ,  Min Jee CHOI ,  Jae Seok CHOI ,  Hyo Sub CHU

IPC: C07K14/00 ,  A61P31/14 ,  G01N33/569

CPC classification number: C07K14/001 ,  A61P31/14 ,  G01N33/56983 ,  G01N2333/165

Abstract: The present invention relates to a peptide for treatment of the corona virus infection COVID-19 and a use thereof. In order to make the binding to the new epitope of SARS-CoV2 RBD stronger compared to the peptide (P6) simulating the conventionally known binding site between SARS-CoV RBD and ACE2, the peptide of the present invention includes a new portion added with a novel amino acid sequence fundamentally designed for interaction in the dimension of atoms consisting of the amino acids. Suggested in the present invention is a novel design of a peptide having higher binding affinity than conventionally known peptides, wherein an expanded peptide is creatively designed to additionally interact with charged amino acids of D420 and K458, located at the rear side of the known binding boundary between RBD and hACE2. The peptide of the present invention exhibits high possibility as a therapeutic agent for COVID-19.